Drug Combination Details
| General Information of the Combination (ID: C39325) | |||||
|---|---|---|---|---|---|
| Name | Glatiramer acetate NP Info | + | Minocycline Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Multiple sclerosis
[ICD-11: 8A40]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | IL5 | Molecule Info |
Pathway MAP
|
|
| In-vivo Model | EAE was induced in C57/BL6 mice by using 50 Ag of the immunogenic myelin oligodendrocyte glycoprotein (MOG) peptide. | |||||
| Experimental
Result(s) |
This combination resulted in a significant reduction of disease severity and disease burden with attenuation of the inflammation, axonal loss and demyelination. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J Neuroimmunol. 2005 Jan;158(1-2):213-21. | |||
